Severe gastritis due to pembrolizumab treatment in a lung cancer patient

Noriko Hayama¹, Hiroaki Ihara¹, Yuichirou Honma¹, Yukinari Itoigawa¹, Kyoichi Kaira² & Mitsuhiro Fujii¹

¹Department of Respiratory Medicine, Koto Hospital, Tokyo, Japan.
²Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.

Keywords
Gastritis, immune checkpoint inhibitors, immune-related adverse events, inflammatory bowel disease, pembrolizumab.

Correspondence
Noriko Hayama, Department of Respiratory Medicine, Koto Hospital, 6-8-5 Ojima, Koto-ku, Tokyo, 136-0072, Japan. E-mail: norico_hayama@yahoo.co.jp

Received: 21 June 2020; Revised: 8 July 2020; Accepted: 9 July 2020; Associate Editor: James Ho.

Respirology Case Reports, 8 (7), 2020, e00636
doi: 10.1002/rcr2.636

Abstract
Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T-lymphocyte antigen-4 (CTLA-4) resembles inflammatory bowel disease (IBD) and that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.

Introduction
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors are known as immune checkpoint inhibitors (ICIs) and are widely used in different types of neoplasms, such as melanoma, lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, and stomach cancer [1]. However, immune-related adverse events (irAEs) involving multiple organs are observed in approximately 60–70% of patients receiving ICIs. ICI-induced gastritis can occur on rare occasions regardless of the presence of colitis, and some case reports have indicated that gastritis can develop in synchrony with cytomegalovirus or Helicobacter pylori infection [2,3]. Clinically, patients with gastritis typically complain of appetite loss, nausea, and vomiting. However, cases with severe ICI-induced gastritis are rare in daily practice, and little is known about the clinical features of patients with severe gastritis caused by ICIs. Here, we present a case with severe gastritis caused by an anti-PD-1 antibody in the patient with non-small cell lung cancer (NSCLC) as well as a review of the relevant literature to elucidate the clinical significance of gastritis secondary to ICIs.

Case Report
A 68-year-old woman was admitted to our hospital with appetite loss, nausea, and vomiting. She had been definitively diagnosed as having pulmonary adenocarcinoma (cT4N2M1b, stage IVA, PD-L1 90%, epidermal growth factor receptor (EGFR) negative, anaplastic lymphoma kinase (ALK) negative, ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1) negative) four years previously. A laboratory investigation exhibited no abnormalities, and a physical examination was unremarkable. Therefore, she received six cycles of a combination of cisplatin, pemetrexed, and bevacizumab as induction therapy, followed by 15 cycles of pemetrexed plus bevacizumab as maintenance therapy. However, she experienced progressive disease, and pembrolizumab was initiated as a second-line treatment. After 25 cycles of pembrolizumab, she complained of appetite loss, but no obvious evidence of
any irAEs aside from the gastrointestinal symptoms was seen. The prescription of oral betamethasone (2 mg) to reduce her symptoms was not effective; on the contrary, her symptoms worsened and she developed nausea, vomiting, and a stomach ache.

A cerebrospinal fluid test, brain magnetic resonance imaging (MRI), and some serological blood examinations did not reveal any abnormalities including cortisol, adrenocorticotropic hormone (ACTH), TSH, free T4, free T3, and sodium except for a slightly elevated C-reactive protein level. An abdominal computed tomography (CT) examination showed diffuse wall thickening in the stomach (Fig. 1), and an upper gastrointestinal endoscopy revealed findings of erythematous and inflammatory changes in the gastric mucosa, suggesting severe gastritis (Fig. 1); no evidence of any colitis was seen during colonoscopy. The pathological findings of a diagnostic biopsy of the gastric mucosa revealed erosion; multiple ulcers; the infiltration of neutrophils, plasma cells, and lymphocytes; and micro-abscesses in the fundic gland mucosa. As severe pembrolizumab-induced gastritis was strongly suspected, treatment with pembrolizumab was stopped and treatment with prednisolone (40 mg/day) was initiated. Her symptoms such as nausea and appetite loss resolved immediately. Likewise, endoscopic findings obtained two weeks later showed an improvement in the gastritis. Stomach biopsies revealed no signs of H. pylori infection or cytomegalovirus infection.

The prednisolone dosage was reduced gradually over a four-month period. Her condition improved, and she has not experienced any recurrence of gastritis as of four months after the cessation of steroid use. She has not received chemotherapy for lung cancer since the cessation of pembrolizumab, but tumour progression has not been observed.

![Computed tomography (CT) image showing gastric wall thickening (A, B) and endoscopic findings showing extensive gastric mucosa erythematous with a white coating (C: pylorus, D: antrum).](image-url)
Immunohistochemical Finding

Using the biopsy sample of the gastric mucosa, PD-L1 (clone SP142; 1:100 dilution; Abcam, Japan), CD4 (1:200 dilution; Dako, Japan), CD8 (1:1000 dilution; Abcam), Foxp3 (1:200 dilution; Dako), and vascular endothelial growth factor receptor (VEGFR2; 1:200 dilution; Abcam) were evaluated using immunohistochemistry (Fig. 2). Immunohistochemical staining was performed for these markers according to previously described procedures [4]. CD4 and CD8 were strongly stained throughout the

Figure 2. Pathological findings of the gastric mucosa biopsy specimen showing erosion, multiple ulcers, and the infiltration of neutrophils, plasma cells, and lymphocytes (A: haematoxylin–eosin stain). Immunohistochemically, the specimen was positive for programmed death ligand-1 (PD-L1) (SP142) (B), CD4 (C), and CD8 (D), the accumulation of Foxp3 was relatively low (E), and the specimen was negative for vascular endothelial growth factor receptor (VEGFR2) (F).
| No | Age | Sex | Types of tumour | Drug | Duration of therapy | Symptoms | Endoscopy findings of stomach | Pathological findings | CMV | Helicobacter pylori | Treatment |
|----|-----|-----|-----------------|------|---------------------|----------|-----------------------------|----------------------|-----|------------------|-----------|
| 1  | 41  | F   | Melanoma        | Pembrolizumab | 10 cycles          | Gastric pain | Severe haemorrhagic gastritis | Neutrophilic infiltration of the lamina propria and gastric glands | −   | −                | Oral prednisone (1 mg/kg) |
| 2  | 44  | M   | Melanoma        | Pembrolizumab | One month          | Dyspepsia and GERD | No abnormality | Lymphocytic gastritis | ND  | −                | ND        |
| 3  | 43  | F   | Melanoma        | Nivolumab     | 13 months          | Gastric pain, anorexia, vomiting, weight loss | Ulcerative and haemorrhagic | Lymphocytic, plasma cell, neutrophils, eosinophils infiltrates | −   | −                | Methylprednisolone IV (1 mg/kg) |
| 4  | 66  | F   | Colon cancer    | Atezolizumab and then pembrolizumab | Five cycles | Dysphagia, gastric pain, nausea, vomiting | Erythematous and ulcerated mucosa | Mononuclear inflammatory cell infiltration in the lamina propria, crypt apoptosis | +   | −                | IV ganciclovir. No steroids |
| 5  | 75  | M   | Bladder carcinoma, Melanoma | Nivolumab | 13 months | Nausea, vomiting, gastric pain | Diffuse mucosal erythema | Severe active and chronic inflammatory infiltrate | −   | −                | Prednisone (0.5 mg/kg) |
| 6  | 93  | F   | Lymphoma        | Nivolumab     | 6 months          | Dysphagia, diarrhoea | Thick mucosal exudates with underlying erythema | Lymphocytes and plasma cells in the lamina propria and epithelial layers | −   | −                | IV prednisone (1 mg/kg) |
| 7  | 77  | M   | Lung carcinoma  | Nivolumab     | Four months (10 courses) | Gastric pain, haematemesis | Haemorrhagic gastritis | Lymphoplasmacytic and neutrophilic infiltration in the fundic gland mucosa | ND  | ND               | Prednisolone (1 mg/kg) |
| 8  | 68  | M   | Lung carcinoma  | Pembrolizumab | Seven cycles       | Gastric pain | Erosion | Lymphocyte-dominant infiltration in the lamina propria | −   | −                | Prednisone IV (1 mg/kg) |
| 9  | 56  | M   | Lung carcinoma  | Nivolumab     | Three weeks        | Diarrhoea | Non-bleeding erosions | −   | ND               | ND        | Symptoms improved without changes in treatment |
| 10 | 45  | F   | Breast carcinoma | Pembrolizumab | ND                | ND (abnormal CT scan) | Diffuse atrophy thickened prepylorus | Chronic active gastritis, severe inflammation, intraepithelial lymphocytes, apoptosis | −   | −                | Increased PPI |
| 11 | 44  | F   | Colon cancer    | Pembrolizumab | ND                | Diarrhoea | Normal | Focal enhancing gastritis with granulomas | −   | −                | Steroid IV, infliximab |
| 12 | 69  | M   | Melanoma        | Nivolumab     | ND                | Nausea, vomiting, diarrhoea | Erythema, erosions | Focal enhancing gastritis | −   | −                | Prednisone, infliximab |
| 13 | 81  | F   | Hodgkin’s disease | Pembrolizumab | ND                | Nausea, vomiting, diarrhoea | Normal | Focal enhancing gastritis | −   | −                | Prednisone |
| 14 | 68  | F   | Lung carcinoma  | Pembrolizumab | 25 courses        | Nausea, appetite loss | Erythematous with white coating | Erosion, multiple ulcer, infiltration of neutrophils, plasma cell, and lymphocytes and micro-abscess in fundic gland mucosa | −   | −                | Prednisolone IV (40 mg) |

CMV, cytomegalovirus; CT, computed tomography; GERD, gastro-esophageal reflux disease; IV, intravenous; ND, not described; PD-1, programmed death-1; PPI, proton pump inhibitor.
whole gastric mucosa, and Foxp3 was weakly stained. There was evidence of some expression of PD-L1 within the gastric cells in the mucosa, but not VEGFR2.

Discussion

ICI-induced gastritis has been reported in some case reports and original articles. Several reports regarding gastritis resulting from CTLA-4 antibody and anti-PD-1 antibody have been published. The reported case series caused by anti-PD-1 antibody alone are listed in Table 1. The patient background characteristics are listed in Table 2. Among the previous reports, five cases had malignant melanoma and three cases had lung cancer, and no specific patient characteristics were seen. Approximately half of the previous cases experienced gastritis within six months after ICI administration, but long-term ICI use was observed in a few cases. Major symptoms included diarrhoea, appetite loss, nausea, vomiting, and stomach ache.

In our case, the patient complained of non-specific symptoms, such as appetite loss and nausea; therefore, a diagnosis of ICI-induced gastritis was initially difficult. In colitis secondary to ICI use, diarrhoea is the most common symptom; however, diarrhoea has also been reported in gastritis patients without colitis [5–7], and gastritis can occur in synchrony with oesophagitis, duodenitis, and colitis [8]. If any symptoms appear during the administration of ICIs, both an upper gastrointestinal endoscopy and colonoscopy are necessary to investigate the possibility of ICI-induced gastritis.

Endoscopic biopsy of the gastric mucosa was useful for a definite diagnosis of ICI-induced gastritis, as it can show different kinds of gastric findings such as erosion, bleeding, and ulcer. The endoscopic observation in the presently reported case suggested a similarity to the gross findings associated with ulcerative colitis, which was supported by the pathological examination. Moreover, our immunohistochemical investigation revealed that there were predominantly infiltrations of CD4 or CD8 lymphocytes [9], rather than regulatory lymphocytes such as Foxp3, and the expression of PD-L1, but not VEGFR2, was seen within the gastric cells in the mucosa. The expression of PD-L1 (SP142) was observed in the infiltrating lymphoid cells and stromal cells. The immune reaction in the gastric mucosa was relatively strong; therefore, there was obvious evidence of severe gastritis related to ICI use. To the best of our knowledge, this is the first report to present the immunohistochemical findings of immune-related gastritis.

As in the presently reported case, steroid therapy is reportedly effective in most cases of ICI-induced gastritis, but a few cases have also required immunosuppressive agents [10].

The incidence of ICI-induced gastritis is relatively rare, compared with colitis, but a massive immunoreaction caused by ICIs can induce severe gastritis. Thus, gastritis should be considered when patients taking ICIs complain of any gastrointestinal symptoms.

Disclosure Statements

Appropriate written informed consent was obtained for publication of this case report and accompanying images. K. Kaira has received research grants and a speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company. All the remaining authors have declared no conflicts of interest.

References

1. Buder-Bakhaya K, and Hassel JC. 2018. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment—a review from the melanoma perspective and beyond. Front. Immunol. 9:1474.
2. Lu J, Firpi-Morell RJ, Dang LH, et al. 2018. An unusual case of gastritis in one patient receiving PD-1 blocking therapy: coexisting immune-related gastritis and cytomegaloviral infection. Gastroenterology Res. 11:383–387.
3. Nishimura Y, Yasuda M, Ocho K, et al. 2018. Severe gastritis after administration of nivolumab and ipilimumab. Case Rep. Oncol. 11:549–556.
4. Kaira K, Shimizu K, Kitahara S, et al. 2018. 2-Deoxy-2-[fluorine-18] fluoro-D-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur. J. Cancer 101:181–190.
5. Zhang ML, Neyaz A, Patil D, et al. 2020. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 76: 233–243.
6. Boike J, and Dejulio T. 2017. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep. J. 12:e57.
7. Gonzalez RS, Salaria SN, Bohannon CD, et al. 2017. PD-1 inhibitor gastroenterocolitis: case series and appraisal of immunomodulatory gastroenterocolitis. Histopathology 70: 558–567.
8. Onuki T, Morita E, Sakamoto N, et al. 2018. Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol. Case Rep. 6:1–3.
9. Gaffuri P, Espeli V, Fulciniti F, et al. 2019. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 111:92–97.
10. Johncilla M, Grover S, Zhang X, et al. 2020. Morphological spectrum of immune checkpoint inhibitor therapy associated gastritis. Histopathology 76:531–539.